clofibric acid has been researched along with Arteriosclerosis in 40 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofibrate is an effective hypolipidemic agent, also lowering the level of fibrinogen." | 5.30 | [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. ( Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999) |
| "During a period of 15 days, 90 geriatric patients with various disturbances in blood lipids and manifestations of cerebral arteriosclerosis ingested 1200 mg/d of N-2-(p-chlorophenoxy)-isobutryl-N'-morpholinomethylurea (plafibride, ITA 104)." | 5.05 | Clinical trials of plafibride in geriatric patients. ( Bracons, R; Bruseghini, L; Demichelis Genesio, MA; Vicens, B; Zapatero, J, 1981) |
| "The effect of several anti-atherogenic drugs (ticlopidine, nicotinic acid and etofibrate) on immune responses and immune complex anaphylaxis has been studied in mice." | 3.67 | Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes. ( Ojeda, G; Portolés, A; Portolés, MP; Rojo, JM, 1985) |
| "Sixty-three patients with type IIa dyslipidemia were randomized to fluvastatin (40 mg daily; n = 33) or simvastatin (20mg daily; n = 30), while 68 type IIb dyslipidemic patients were treated with micronized ciprofibrate (100mg daily; n = 34) or micronized fenofibrate (200mg daily; n = 34)." | 2.71 | The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. ( Belowski, D; Herman, ZS; Kowalski, J; Krysiak, R; Labuzek, K; Madej, A; Okopień, B; Zieliński, M, 2004) |
| "Ciprofibrate did not inhibit thromboxane B 2 synthesis in platelets." | 2.70 | Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. ( Cibulová, L; Dzúrik, R; Gajdos, M; Huttová, D; Krivosíková, Z; Mongiellová, V; Spustová, V, 2001) |
| "Etofibrate is a hypolipemic drug belonging to the fibrate class." | 2.69 | Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome. ( Chelstowski, K; Jastrzebska, M; Kopciewicz, J; Naruszewicz, M; Pieczul-Mróz, J; Torbus-Lisiecka, B, 1999) |
| "Ciprofibrate has a potent hypolipidemic effect, especially a decrease in triglycerides, VLDL and fibrinogen, and an increase in HDL-cholesterol, but does not influence glycemic control nor insulin action." | 2.69 | Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects. ( Ascaso, JF; Carmena, R; Hernández-Mijares, A; Lluch, I; Martínez-Triguero, ML; Vizcarra, E, 2000) |
| "Dyslipidaemia in patients with type 2 diabetes commonly consists of elevated triglyceride levels; normal or slightly elevated low-density lipoprotein (LDL)-cholesterol levels with a preponderance of small, dense LDL particles; and low high-density lipoprotein (HDL)-cholesterol levels with a preponderance of small, dense HDL." | 2.42 | LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit? ( Taskinen, MR, 2003) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "Ciprofibrate is a hypolipidaemic compound that acts primarily by enhancing the oxidation of fatty acids in the liver and, consequently, decreasing the production of hepatic VLDL." | 1.32 | The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. ( Borensztajn, J; Fu, T; Kashireddy, P, 2003) |
| "Ciprofibrate is an effective hypolipidemic agent, also lowering the level of fibrinogen." | 1.30 | [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. ( Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999) |
| " The drug was administered at four dosage levels during induction of arteriosclerosis in order to establish a possible dose-effect relationship." | 1.27 | Hypolipemic profile of plafibride in a model of experimental atherosclerosis. ( Badimón, JJ; Cánovas, M; Padró, T; Vidal, M; Villaverde, CA, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (25.00) | 18.7374 |
| 1990's | 8 (20.00) | 18.2507 |
| 2000's | 22 (55.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, T | 2 |
| Kashireddy, P | 1 |
| Borensztajn, J | 2 |
| Taskinen, MR | 1 |
| Guerin, M | 1 |
| Le Goff, W | 1 |
| Frisdal, E | 1 |
| Schneider, S | 1 |
| Milosavljevic, D | 1 |
| Bruckert, E | 1 |
| Chapman, MJ | 1 |
| Mukhopadhyay, D | 1 |
| Davidson, NO | 1 |
| Okopień, B | 1 |
| Krysiak, R | 1 |
| Kowalski, J | 1 |
| Madej, A | 1 |
| Belowski, D | 1 |
| Zieliński, M | 1 |
| Labuzek, K | 1 |
| Herman, ZS | 1 |
| van Raalte, DH | 1 |
| Li, M | 1 |
| Pritchard, PH | 1 |
| Wasan, KM | 1 |
| Rabasseda, X | 1 |
| Sebestjen, M | 1 |
| Keber, I | 1 |
| Zegura, B | 1 |
| Simcic, S | 1 |
| Bozic, M | 1 |
| Fressart, MM | 1 |
| Stegnar, M | 1 |
| Benz, R | 1 |
| Suter, PM | 1 |
| Asano, M | 1 |
| Yamada, N | 1 |
| Wierzbicki, AS | 1 |
| Vergès, B | 1 |
| Dunbar, RL | 1 |
| Rader, DJ | 1 |
| Tavintharan, S | 1 |
| Lim, SC | 1 |
| Sum, CF | 1 |
| Gizard, F | 1 |
| Staels, B | 2 |
| Fukumoto, Y | 1 |
| Shimokawa, H | 1 |
| Segarra Domènech, J | 1 |
| Santafé Oroz, J | 1 |
| Lasierra, J | 1 |
| Díez, MM | 1 |
| Fernández, A | 1 |
| Viladés, E | 1 |
| Gil, M | 1 |
| Velázquez, E | 1 |
| Priego, JG | 1 |
| Díaz Méndez, M | 1 |
| Degenring, FH | 1 |
| Schatton, W | 1 |
| Hotz, W | 1 |
| Badimón, JJ | 1 |
| Padró, T | 1 |
| Cánovas, M | 1 |
| Vidal, M | 1 |
| Villaverde, CA | 1 |
| Demichelis Genesio, MA | 1 |
| Bracons, R | 1 |
| Vicens, B | 1 |
| Zapatero, J | 1 |
| Bruseghini, L | 1 |
| Mertz, DP | 1 |
| Suermann, I | 1 |
| Göhmann, E | 1 |
| Irizar, A | 1 |
| Ioannides, C | 1 |
| Schonfeld, G | 1 |
| Fincham, JE | 1 |
| Quack, G | 2 |
| Wülfroth, P | 1 |
| Benadé, AJ | 1 |
| Sinzinger, H | 1 |
| Jastrzebska, M | 1 |
| Torbus-Lisiecka, B | 1 |
| Pieczul-Mróz, J | 1 |
| Chelstowski, K | 1 |
| Kopciewicz, J | 1 |
| Naruszewicz, M | 1 |
| Gajdos, M | 2 |
| Fedelesova, V | 1 |
| Mongiellova, V | 2 |
| Cibulova, L | 2 |
| Huttova, D | 2 |
| Polak, F | 1 |
| Krivosikova, Z | 2 |
| Paragh, G | 1 |
| Balogh, Z | 1 |
| Watts, GF | 1 |
| Dimmitt, SB | 1 |
| Hernández-Mijares, A | 1 |
| Lluch, I | 1 |
| Vizcarra, E | 1 |
| Martínez-Triguero, ML | 1 |
| Ascaso, JF | 1 |
| Carmena, R | 1 |
| Dobiásová, M | 1 |
| Frohlich, J | 1 |
| Fruchart, JC | 1 |
| Duriez, P | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Spustová, V | 1 |
| Dzúrik, R | 1 |
| Betz, E | 2 |
| Moreau, P | 1 |
| Jacotot, B | 1 |
| Tillement, JP | 1 |
| Rojo, JM | 1 |
| Portolés, MP | 1 |
| Ojeda, G | 1 |
| Portolés, A | 1 |
| Hämmerle, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation in Both Skeletal Muscle and Adipose Tissue[NCT01911091] | 56 participants (Anticipated) | Interventional | 2013-07-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for clofibric acid and Arteriosclerosis
| Article | Year |
|---|---|
LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Controlled Clinical Trials as | 2003 |
Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future.
Topics: Arteriosclerosis; Clofibric Acid; Fatty Acids; Gene Expression Regulation; Humans; Lipoproteins; Pol | 2004 |
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric A | 2004 |
[Dyslipidemia management in patients with impaired glucose tolerance].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Clofibric Acid; Eicosapen | 2005 |
Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
Topics: Arteriosclerosis; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Disease Progression; Hu | 2005 |
Diabetic dyslipidaemia: insights for optimizing patient management.
Topics: Arteriosclerosis; Cardiovascular Agents; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopa | 2005 |
Demystifying triglycerides: a practical approach for the clinician.
Topics: Arteriosclerosis; Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2005 |
Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
Topics: Apoproteins; Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, H | 2005 |
[Adverse effects of lipid-lowering medications].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clofibric Acid; Contraindications; Humans; Hydroxymethyl | 2007 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Ge | 1983 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fib | 1994 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagu | 1998 |
[Effect of fibrates on lipid metabolism and the blood coagulation system].
Topics: Arteriosclerosis; Blood Coagulation; Clofibric Acid; Fibrinogen; Hemostasis; Humans; Lipid Metabolis | 2000 |
Fibrates, dyslipoproteinaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clin | 1999 |
The role of fibric acids in atherosclerosis.
Topics: Arteriosclerosis; Cardiovascular System; Clofibric Acid; Fatty Acids, Nonesterified; Gene Expression | 2001 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
7 trials available for clofibric acid and Arteriosclerosis
| Article | Year |
|---|---|
Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
Topics: Adult; Animals; Apolipoprotein A-I; Apolipoproteins B; Arteriosclerosis; Cholesterol; Cholesterol Es | 2003 |
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.
Topics: Adult; Aged; Arteriosclerosis; Clofibric Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2004 |
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Prote | 2004 |
Clinical trials of plafibride in geriatric patients.
Topics: Aged; Arteriosclerosis; Clofibrate; Clofibric Acid; Female; Humans; Hypolipidemic Agents; Lipids; Ma | 1981 |
Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Diabetes Mellitus, Type 1; Factor VII; Fibrinogen; Humans; Hyperli | 1999 |
Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
Topics: Adult; Aged; Apolipoproteins B; Area Under Curve; Arteriosclerosis; Blood Glucose; Carbohydrate Meta | 2000 |
Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fi | 2001 |
17 other studies available for clofibric acid and Arteriosclerosis
| Article | Year |
|---|---|
The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E.
Topics: Animals; Apolipoproteins; Arteriosclerosis; Blotting, Northern; Blotting, Western; Clofibric Acid; F | 2003 |
The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
Topics: Animals; Aorta; Apolipoproteins B; Arteriosclerosis; Blotting, Western; Cholesterol; Clofibric Acid; | 2004 |
Highlights from the 74th Congress of the European Atherosclerosis Society.
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Cholesterol; Clofibric Acid; Humans; Hydroxymeth | 2004 |
[The fibrate-activated PPARalpha/p16INK4A pathway inhibits vascular smooth muscle cell proliferation and vascular occlusion].
Topics: Animals; Arteriosclerosis; Cell Division; Cholesterol; Clofibric Acid; Coronary Restenosis; Cyclin-D | 2006 |
[Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2].
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Clofibrate; Clofibric Acid; Diet, Atherogenic; Epoprosten | 1983 |
[Pharmacologic therapy of arteriosclerosis: current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clofibrate; Clofibric Acid; Humans | 1984 |
[Atherosclerosis treatment with etofibrate retard. New perspectives].
Topics: Arteriosclerosis; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparation | 1983 |
Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Hypoli | 1983 |
[Etofibrate lowers the atherosclerosis index].
Topics: Arteriosclerosis; Clofibrate; Clofibric Acid; Humans; Lipids | 1981 |
Expression and inducibility of cytochrome P450 proteins belonging to families 2,3 and 4 in the rabbit aorta.
Topics: Animals; Aorta; Arteriosclerosis; Clofibric Acid; Cytochrome P-450 Enzyme System; Enzyme Induction; | 1995 |
Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Body Weight; Chlorocebus aethiops; Clofibric Acid; Coron | 1996 |
[The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fi | 1999 |
[The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Topics: Adult; Aged; Arteriosclerosis; Child; Cholesterol; Cholesterol, HDL; Clofibric Acid; Esterification; | 2000 |
Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis.
Topics: Animals; Arteriosclerosis; Clofibrate; Clofibric Acid; Disease Models, Animal; Hypolipidemic Agents; | 1990 |
Experimental pharmacological study of moroxybrate, a hypolipidaemic, antithrombotic, antiatheromatous agent.
Topics: Animals; Anticoagulants; Arteriosclerosis; Clofibrate; Clofibric Acid; Dietary Fats; Fibrinolytic Ag | 1987 |
Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes.
Topics: Anaphylaxis; Animals; Antibody Formation; Antigen-Antibody Complex; Arteriosclerosis; Clofibrate; Cl | 1985 |
Effect of etofibrate and its metabolites on atheromas of rabbits and on smooth muscle cell cultures.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Carotid Arteries; Cell Division; Cells, | 1986 |